Ratings NovoCure Limited

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 13/09/2024 BST			5-day change	1st Jan Change
18.57 ^USD	+7.16%		+10.01%	+24.38%

09-03	NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	MT
09-03	Novocure Announces CEO Changes, Effective January 1, 2025	CI

The company presents an interesting fundamental situation from a short-term investment perspective.

Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
With an enterprise value anticipated at 3.58 times the sales for the current fiscal year, the company turns out to be overvalued.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Source: Surperformance

Source: Refinitiv

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
NOVOCURE LIMITED	-	2.01B
PENUMBRA, INC.		7.26B
MASIMO CORPORATION	-	6.03B
GETINGE AB		5.94B
ASAHI INTECC CO., LTD.		5.07B
APT MEDICAL INC.		4.45B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.		4.35B
INARI MEDICAL, INC.	-	2.71B
SKAN GROUP AG		2.15B
Average		4.44B
Weighted average by Cap.